Brokerages Anticipate Tango Therapeutics, Inc. (NASDAQ:TNGX) Will Post Quarterly Sales of $5.97 Million

Analysts predict that Tango Therapeutics, Inc. (NASDAQ:TNGXGet Rating) will post $5.97 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Tango Therapeutics’ earnings, with estimates ranging from $5.80 million to $6.13 million. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Tango Therapeutics will report full year sales of $23.57 million for the current financial year, with estimates ranging from $23.00 million to $24.13 million. For the next financial year, analysts anticipate that the business will report sales of $23.75 million, with estimates ranging from $23.00 million to $24.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Tango Therapeutics.

Tango Therapeutics (NASDAQ:TNGXGet Rating) last released its quarterly earnings results on Monday, March 28th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $5.72 million for the quarter, compared to the consensus estimate of $6.12 million.

Separately, Zacks Investment Research raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research report on Wednesday, April 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $13.75.

NASDAQ:TNGX opened at $5.57 on Monday. Tango Therapeutics has a 52 week low of $4.41 and a 52 week high of $18.84. The firm’s 50-day simple moving average is $7.04 and its 200 day simple moving average is $8.92.

A number of hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. bought a new position in Tango Therapeutics in the 3rd quarter valued at about $41,000. Royal Bank of Canada bought a new stake in shares of Tango Therapeutics during the 1st quarter valued at approximately $32,000. Marshall Wace LLP bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at approximately $68,000. Swiss National Bank grew its holdings in shares of Tango Therapeutics by 7.4% during the 1st quarter. Swiss National Bank now owns 93,100 shares of the company’s stock valued at $706,000 after purchasing an additional 6,400 shares during the last quarter. Finally, Penserra Capital Management LLC bought a new stake in shares of Tango Therapeutics during the 3rd quarter valued at approximately $133,000. 77.28% of the stock is currently owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile (Get Rating)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Read More

Get a free copy of the Zacks research report on Tango Therapeutics (TNGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.